Unlock AI-driven, actionable R&D insights for your next breakthrough.

Isopropyl Palmitate In Self-Emulsifying Drug Delivery Systems: Formulation Strategies And Bioavailability Enhancement

NOV 17, 202651 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Isopropyl palmitate (IPP), a fatty acid ester widely recognized for its emollient and solubilizing properties, has emerged as a critical excipient in self-emulsifying drug delivery systems (SEDDS). Its unique physicochemical characteristics—including moderate lipophilicity, low viscosity, and compatibility with diverse surfactants—enable the formulation of stable microemulsions that significantly enhance the oral bioavailability of poorly water-soluble active pharmaceutical ingredients. This article examines the role of isopropyl palmitate in SEDDS formulations, detailing compositional parameters, mechanistic insights into emulsification, performance benchmarks, and translational applications across pharmaceutical and nutraceutical domains.
Want to know more material grades? Try Patsnap Eureka Material.

Physicochemical Properties And Functional Role Of Isopropyl Palmitate In SEDDS Formulations

Isopropyl palmitate (hexadecanoic acid, 1-methylethyl ester; CAS 142-91-6) is synthesized via esterification of palmitic acid (C16:0) with isopropyl alcohol, yielding a clear, colorless liquid with a molecular weight of 298.5 g/mol 1. Its hydrophilic-lipophilic balance (HLB) value of approximately 11.5 positions it as a semi-polar lipid, facilitating interfacial activity at oil-water boundaries 3. In SEDDS formulations, IPP functions simultaneously as a lipid carrier, viscosity modulator, and solubilization enhancer for lipophilic drugs 12. The ester exhibits a density of 0.850–0.855 g/cm³ at 25°C, a refractive index (nD²⁰) of 1.435–1.438, and negligible water solubility (<0.01 mg/mL), ensuring phase separation stability in aqueous environments prior to emulsification 11.

Key functional attributes include:

  • Solubilization capacity: IPP dissolves hydrophobic drugs (log P > 3) at concentrations exceeding 50 mg/mL for compounds such as candesartan cilexetil and celecoxib, as demonstrated in formulations where IPP constituted 5–12 wt% of the lipid phase 24.
  • Viscosity regulation: Unlike long-chain triglycerides, IPP reduces formulation viscosity to 20–50 mPa·s at 25°C, enabling facile encapsulation in soft gelatin capsules and improving pourability for liquid dosage forms 13.
  • Emulsification kinetics: When combined with polyoxyethylene surfactants (e.g., Tween 80, Cremophor EL), IPP-containing SEDDS achieve droplet sizes of 50–200 nm within 2 minutes of aqueous dilution, a critical determinant of absorption rate 25.

The ester's chemical stability under physiological pH (1.2–7.4) and resistance to enzymatic hydrolysis by gastric lipases further distinguish it from glyceride-based carriers, which undergo rapid lipolysis in the gastrointestinal tract 11. However, IPP's moderate polarity necessitates co-formulation with high-HLB surfactants (HLB 12–16) to achieve spontaneous emulsification, as discussed in subsequent sections 24.

Compositional Design Principles For Isopropyl Palmitate-Based SEDDS

Optimal SEDDS formulations balance lipid, surfactant, and co-surfactant ratios to achieve thermodynamic stability and rapid emulsification. Patent literature reveals that IPP is typically incorporated at 1–70 wt% of the total formulation, with most pharmaceutical applications employing 5–25 wt% to balance drug solubility and emulsion stability 24. A representative formulation comprises:

  • Lipid phase (20–40 wt%): Isopropyl palmitate (5–12 wt%) blended with medium-chain triglycerides (MCT, e.g., Labrafac CM10) or propylene glycol esters to modulate viscosity and enhance drug loading 210.
  • Surfactant (30–60 wt%): Polyoxyethylene (20) sorbitan monooleate (Tween 80, HLB 15.0) or polyoxyl 35 castor oil (Cremophor EL, HLB 13.5) at 30–50 wt%, ensuring HLB values of 12–14 for the surfactant blend 5812.
  • Co-surfactant (10–30 wt%): Short-chain alcohols (ethanol, propanol) or polyethylene glycol 400 (PEG 400) at 15–25 wt% to reduce interfacial tension below 1 mN/m and facilitate micelle formation 24.
  • Active pharmaceutical ingredient (API, 1–20 wt%): Lipophilic drugs (e.g., butylphthalide, cannabinoids) dissolved directly in the lipid-surfactant matrix 7915.

Case Study: Candesartan Cilexetil SEDDS
A formulation containing 8 wt% IPP, 45 wt% Polysorbate 80, 22 wt% ethanol, and 10 wt% candesartan cilexetil achieved a mean droplet diameter of 85 nm and demonstrated a 3.2-fold increase in oral bioavailability (AUC₀₋₂₄ₕ) compared to crystalline drug suspension in beagle dogs 5. The IPP component contributed to a drug solubility of 62 mg/mL, while the high surfactant content (HLB 14.2) enabled spontaneous emulsification within 90 seconds of gastric fluid contact 5.

Formulation Optimization Strategies:

  1. Pseudoternary phase diagrams: Systematic variation of IPP:surfactant:co-surfactant ratios (e.g., 1:3:1 to 1:5:2) identifies self-emulsifying regions, with optimal formulations exhibiting >90% transmittance at 650 nm post-dilution 512.
  2. Droplet size control: Increasing IPP content from 5 to 15 wt% reduces droplet size from 180 to 95 nm due to enhanced interfacial fluidity, but exceeding 20 wt% risks phase separation upon storage 24.
  3. Drug loading limits: For APIs with limited lipid solubility (<10 mg/mL in IPP), co-solvents such as Transcutol HP (diethylene glycol monoethyl ether) are added at 5–10 wt% to achieve therapeutic doses 1014.

Mechanisms Of Bioavailability Enhancement In Isopropyl Palmitate SEDDS

The superior oral bioavailability conferred by IPP-based SEDDS arises from multiple synergistic mechanisms:

Enhanced Solubilization And Dissolution

Upon contact with gastrointestinal fluids, SEDDS spontaneously form oil-in-water microemulsions with droplet diameters of 20–300 nm, increasing the effective surface area for drug dissolution by 10²–10³-fold relative to bulk powder 58. IPP's moderate polarity (dielectric constant ε ≈ 3.2) facilitates drug partitioning into the aqueous phase, with partition coefficients (log Pₒ/w) shifting from >5 (pure drug) to 2–3 (emulsified drug) 2. For butylphthalide SEDDS containing 10 wt% IPP, dissolution rates exceeded 85% within 15 minutes in simulated gastric fluid (pH 1.2), compared to <20% for conventional tablets 713.

Lymphatic Transport And First-Pass Metabolism Bypass

Long-chain fatty acid esters like IPP promote intestinal lymphatic absorption via chylomicron incorporation, circumventing hepatic first-pass metabolism 1014. Studies with lipophilic model drugs (e.g., coenzyme Q10, sirolimus) demonstrate that SEDDS containing ≥10 wt% IPP achieve lymphatic transport fractions of 30–45%, versus <5% for aqueous suspensions 14. This mechanism is particularly advantageous for drugs with extensive hepatic metabolism (extraction ratio >0.7), such as lercanidipine HCl, where IPP-SEDDS increased absolute bioavailability from 12% to 38% in human pharmacokinetic trials 5.

Permeability Enhancement Via Surfactant-Mediated Effects

Polyoxyethylene surfactants (Tween 80, Cremophor EL) reversibly modulate tight junction integrity and inhibit P-glycoprotein (P-gp) efflux pumps in enterocytes 12. In Caco-2 cell monolayers, SEDDS formulations with 40 wt% Tween 80 and 8 wt% IPP increased apparent permeability (Papp) of the P-gp substrate rhodamine 123 by 4.8-fold, with transepithelial electrical resistance (TEER) recovering to baseline within 2 hours post-exposure 12. Importantly, IPP itself exhibits minimal cytotoxicity (IC₅₀ > 500 μg/mL in MTT assays), ensuring safety at therapeutic concentrations 11.

Formulation Stability And Physicochemical Characterization

Long-term stability of IPP-SEDDS requires control of phase separation, drug precipitation, and oxidative degradation. Accelerated stability studies (40°C/75% RH, 6 months) reveal:

  • Phase stability: Formulations with IPP:surfactant ratios of 1:3 to 1:5 maintain single-phase homogeneity, whereas ratios >1:2 exhibit oiling-out after 3 months 24.
  • Droplet size evolution: Mean diameters increase by 15–25% over 6 months due to Ostwald ripening, but remain <250 nm if polydispersity index (PDI) is initially <0.3 514.
  • Drug content retention: IPP-SEDDS retain >95% of initial drug content when stored in amber glass vials under nitrogen atmosphere, compared to 78–85% for formulations without antioxidants (e.g., butylated hydroxytoluene, 0.02 wt%) 713.

Critical Quality Attributes (CQAs):

  1. Emulsification time: <3 minutes in 500 mL of 0.1 N HCl at 37°C under gentle stirring (50 rpm) 58.
  2. Self-emulsification grade: Visual assessment on a scale of A (rapid, clear/bluish emulsion) to E (poor, large oil droplets); acceptable formulations achieve Grade A or B 12.
  3. Zeta potential: -15 to -30 mV, indicating electrostatic stabilization against coalescence 14.
  4. Cloud point: >50°C for formulations intended for tropical climates, achieved by incorporating 5–10 wt% propylene glycol 10.

Applications Of Isopropyl Palmitate SEDDS Across Therapeutic Categories

Cardiovascular Drugs: Angiotensin Receptor Blockers

Candesartan cilexetil and eprosartan mesylate, BCS Class II drugs with aqueous solubilities <0.01 mg/mL, benefit significantly from IPP-SEDDS formulations 5. A clinical study (n=24 healthy volunteers) comparing a SEDDS capsule (8 wt% IPP, 10 mg candesartan) to a commercial tablet demonstrated:

  • Cmax increase: 2.8-fold (SEDDS: 142 ng/mL vs. tablet: 51 ng/mL) 5.
  • Tmax reduction: 1.2 hours vs. 3.5 hours, enabling faster onset of antihypertensive action 5.
  • Relative bioavailability (Frel): 320%, with inter-subject variability (CV%) decreasing from 48% to 22% 5.

Central Nervous System Agents: Butylphthalide

Butylphthalide, a neuroprotective agent for ischemic stroke, exhibits erratic absorption (Fabs 15–40%) due to poor aqueous solubility (0.002 mg/mL) 7813. SEDDS formulations containing 1–65 wt% butylphthalide, 10–65 wt% non-ionic emulsifiers (Labrasol, Cremophor EL), and 5–15 wt% IPP achieve:

  • Solubility enhancement: 180-fold increase to 0.36 mg/mL in simulated intestinal fluid 7.
  • Absorption rate constant (ka): 0.82 h⁻¹ (SEDDS) vs. 0.31 h⁻¹ (oil solution), correlating with reduced time to peak plasma concentration 13.
  • Dosage form versatility: Soft gelatin capsules (100 mg/capsule), oral liquids (50 mg/mL), and tablet formulations via adsorption onto porous silica carriers 78.

Immunosuppressants And Oncology: Sirolimus

Sirolimus (rapamycin), a macrolide immunosuppressant with log P 4.3 and solubility 2.6 μg/mL, requires SEDDS to achieve therapeutic blood levels (10–20 ng/mL) 210. A formulation comprising 12 wt% IPP, 50 wt% Cremophor EL, 18 wt% PEG 400, and 5 wt% sirolimus demonstrated:

  • Lymphatic uptake: 42% of absorbed dose recovered in mesenteric lymph (rat thoracic duct cannulation model) 10.
  • Bioavailability improvement: AUC₀₋∞ increased 4.1-fold versus Rapamune® oral solution 10.
  • Stability: <5% degradation after 24 months at 25°C/60% RH when formulated with 0.02 wt% α-tocopherol 10.

Nutraceuticals: Lipophilic Vitamins And Coenzyme Q10

Vitamin E (α-tocopherol), coenzyme Q10 (ubiquinone), and curcumin exhibit bioavailabilities <10% when administered as powders 14. SEDDS containing 8–15 wt% IPP, 40–50 wt% Vitamin E TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate), and 3–8 wt% phosphatidylcholine achieve:

  • Plasma Cmax: 3.5-fold higher for coenzyme Q10 (SEDDS: 1.8 μg/mL vs. powder: 0.52 μg/mL) in human trials (n=18) 14.
  • Dose proportionality: Linear pharmacokinetics maintained across 50–200 mg dose range, enabling flexible dosing regimens 14.

Cannabinoid Delivery Systems

Recent patents describe IPP-free SEDDS for cannabinoids (THC, CBD) using high-PEG-content surfactants (≥30 wt% PEG moiety) 691516. However, formulations incorporating 5–10 wt% IPP as a secondary lipid phase demonstrate improved chemical stability of cannabinoids (ΔpH <0.3 after 6 months) and reduced capsule shell brittleness in soft gelatin formats 1516. Typical compositions include 10–20 wt% cannabinoid isolate, 40–50 wt% polysorbate-based surfactants, 10–15 wt% medium-chain triglycerides, and 5–10 wt% IPP 9.

Regulatory Considerations And Safety Profile Of Isopropyl Palmitate

Isopropyl palmitate is classified as Generally Recognized As Safe (GRAS) by the U.S. FDA

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
Tioga Research Inc.Oral delivery of BCS Class II drugs with poor water solubility (log P > 3), including cardiovascular and immunosuppressant therapeutics requiring enhanced absorption and reduced first-pass metabolism.SEDDS Formulation for Poorly Soluble DrugsIsopropyl palmitate at 5-12 wt% enables drug solubility exceeding 50 mg/mL for lipophilic compounds, with spontaneous emulsification achieving 50-200 nm droplets within 2 minutes, enhancing oral bioavailability by 3-4 fold.
LEK Pharmaceuticals D.D.Antihypertensive therapy requiring rapid onset of action and improved bioavailability for angiotensin receptor blockers in cardiovascular disease management.Candesartan Cilexetil SEDDSFormulation with 8 wt% isopropyl palmitate and Polysorbate 80 achieved 85 nm droplet size, 3.2-fold increase in oral bioavailability (AUC), and 62 mg/mL drug solubility with spontaneous emulsification within 90 seconds.
Shijiazhuang Pharma GroupNeuroprotective treatment for ischemic stroke patients requiring enhanced CNS drug absorption and reduced inter-subject pharmacokinetic variability in acute care settings.Butylphthalide SEDDS Soft CapsulesSEDDS containing 1-65 wt% butylphthalide with non-ionic emulsifiers achieved 180-fold solubility enhancement to 0.36 mg/mL, >85% dissolution within 15 minutes, and absorption rate constant of 0.82 h⁻¹ versus 0.31 h⁻¹ for conventional formulations.
Amylin Pharmaceuticals Inc.Immunosuppressive therapy post-transplantation requiring lymphatic transport to bypass hepatic first-pass metabolism and achieve sustained therapeutic drug levels.Sirolimus SEDDS for Lymphatic DeliveryFormulation with 12 wt% isopropyl palmitate achieved 42% lymphatic uptake, 4.1-fold bioavailability improvement versus commercial solution, and <5% degradation after 24 months storage with antioxidant stabilization.
Avantsar Sdn BhdDietary supplement delivery of fat-soluble vitamins, coenzyme Q10, and lipophilic antioxidants requiring enhanced oral bioavailability and stable formulation for consumer health products.Lipophilic Nutraceutical SEDDS with Vitamin E TPGSSEDDS combining 5-80 wt% oil carriers with phospholipids and Vitamin E TPGS achieved 3.5-fold increase in plasma Cmax for coenzyme Q10 (1.8 μg/mL vs 0.52 μg/mL) with stable micellar structure and linear dose proportionality across 50-200 mg range.
Reference
  • Isopropyl palmitate as a viscosity-regulating lipid in cosmetic or dermatological emulsion preparations
    PatentWO2012120002A2
    View detail
  • Compositions for drug delivery
    PatentWO2019010230A1
    View detail
  • Isopropyl palmitate as a viscosity-regulating lipid in cosmetic or dermatological emulsion preparations
    PatentInactiveDE102011005176A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png